Literature DB >> 14529136

Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001).

Tracy L Gieger1, Alain P Théon, Jonathan A Werner, Margaret C McEntee, Kenneth M Rassnick, Hilde E V DeCock.   

Abstract

The medical records of 24 dogs with histologically confirmed mast cell tumors (MCT) of the muzzle were retrospectively evaluated to determine their biologic behavior and prognostic factors. Information on signalment, tumor grade and stage, treatment methods, and pattern of and time to failure and death was obtained from the medical record. Twenty-three dogs were treated with combinations of radiotherapy, surgery, and chemotherapy; 1 dog received no treatment. There were 2 Grade 1, 15 Grade 11, and 7 Grade III tumors. Tumors were stage 0 (n = 8), stage 1 (5), stage 2 (6), stage 3 (4), and stage 4 (1). Mean and median survival times of treated dogs were 36 and 30 months, respectively. Prognostic factors affecting survival time included tumor grade and presence of metastasis at diagnosis. Dogs with Grade I and II tumors survived longer than dogs with Grade III tumors. Variables, including sex, age, gross versus microscopic disease, and treatment type were not found to affect survival. Local control rate was 75% at 1 year and 50% at 3 years. Tumor grade was the only variable found to affect local control. Dogs with Grade I tumors had longer disease-free intervals than those with Grade II tumors, and dogs with Grade II tumors had longer disease-free intervals than dogs with Grade III tumors. Eight of 9 dogs dying of MCT had local or regional disease progression. Muzzle MCT a rebiologically aggressive tumors with higher regional metastatic rates than previously reported for MCT in other sites.

Entities:  

Mesh:

Year:  2003        PMID: 14529136     DOI: 10.1111/j.1939-1676.2003.tb02501.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  7 in total

1.  Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology.

Authors:  Ehsan Hosseini; Behnam Pedram; Ali Mohammad Bahrami; Seyed Rashid Touni; Hamed Zamankhan Malayeri; Aram Mokarizadeh; Mehdi Pourzaer; Maryam Pourzaer; Shahram Zehtabian; Sheida Mohajer; Sharareh Ahmadi
Journal:  Tumour Biol       Date:  2014-10-15

2.  Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.

Authors:  C Robat; C London; L Bunting; L McCartan; N Stingle; K Selting; I Kurzman; D M Vail
Journal:  Vet Comp Oncol       Date:  2011-01-31       Impact factor: 2.613

3.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

4.  Intranasal mast cell tumor in the dog: A case series.

Authors:  Alison Khoo; Amy Lane; Ken Wyatt
Journal:  Can Vet J       Date:  2017-08       Impact factor: 1.008

5.  Evaluation of information presented within mast cell tumour histopathology reports in the United States: 2012-2015.

Authors:  Jennifer K Reagan; Laura E Selmic; Caroline Fallon; Elizabeth A Driskell; Laura D Garrett
Journal:  Vet Med Sci       Date:  2018-06-07

6.  Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.

Authors:  Jaime A Olsen; Maurine Thomson; Kathleen O'Connell; Ken Wyatt
Journal:  Vet Med Sci       Date:  2018-05-24

7.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.